Sign in to view content

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

Carl D. Regillo, MD

Video
Published 2022

Related

Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more